LUMO Logo

Lumos Pharma, Inc. (LUMO) 

NASDAQ
Market Cap
$37.54M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
604 of 774
Rank in Industry
325 of 432

Largest Insider Buys in Sector

LUMO Stock Price History Chart

LUMO Stock Performance

About Lumos Pharma, Inc.

Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare endocrine disorders. The company is headquartered in Austin, Texas.

Insider Activity of Lumos Pharma, Inc.

Over the last 12 months, insiders at Lumos Pharma, Inc. have bought $0 and sold $0 worth of Lumos Pharma, Inc. stock.

On average, over the past 5 years, insiders at Lumos Pharma, Inc. have bought $1.52M and sold $1.74M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 4,000 shares for transaction amount of $20,120 was made by McCracken Joseph S (director) on 2022‑11‑16.

List of Insider Buy and Sell Transactions, Lumos Pharma, Inc.

2023-08-02SaleChief Scientific Officer
3,407
0.0418%
$3.21$10,919-8.84%
2023-04-04SaleChief Scientific Officer
2,214
0.027%
$3.27$7,240-3.74%
2023-02-02SaleChief Scientific Officer
439
0.0054%
$3.53$1,550-5.49%
2022-11-16Purchasedirector
4,000
0.0494%
$5.03$20,120-29.42%
2022-09-23PurchaseChief Executive Officer
208
0.0024%
$8.80$1,830-61.56%
2022-09-21PurchaseChief Executive Officer
2,214
0.0264%
$8.84$19,572-60.70%
2022-09-20PurchaseChief Executive Officer
1,506
0.0178%
$8.75$13,178-60.59%
2022-09-19PurchaseChief Executive Officer
541
0.0064%
$8.65$4,680-59.77%
2021-09-08SaleChief Scientific Officer
2,214
0.027%
$11.30$25,018-23.62%
2021-09-08Purchasedirector
10,000
0.121%
$11.21$112,116-23.62%
2021-09-07Purchasedirector
10,000
0.1194%
$11.11$111,139-23.97%
2021-09-03Purchasedirector
8,100
0.0969%
$11.35$91,905-25.37%
2021-09-02Purchasedirector
6,300
0.0745%
$11.23$70,739-25.35%
2021-09-01Purchasedirector
4,589
0.0546%
$10.87$49,892-22.19%
2021-08-31Purchasedirector
6,000
0.0708%
$10.70$64,181-21.61%
2021-08-30Purchasedirector
8,625
0.1023%
$10.52$90,738-19.60%
2021-08-27Purchasedirector
4,981
0.0595%
$10.50$52,282-18.73%
2021-08-26Purchasedirector
6,200
0.0736%
$10.07$62,430-15.76%
2021-08-25Purchasedirector
14,900
0.1769%
$9.87$147,078-14.07%
2021-08-24Purchasedirector
10,775
0.1275%
$9.45$101,871-10.41%

Insider Historical Profitability

<0.0001%
Stine Seed Farm, Inc.10 percent owner
7857732
90.8553%
$4.3430+18.87%
LALANDE KEVIN M.director
730446
8.4458%
$4.34190<0.0001%
Link Charles J. Jr.Chairman of the Board and CEO
282756
3.2694%
$4.34168<0.0001%
Lundquist David J.director
87630
1.0132%
$4.3410+62.86%
HENNEMAN JOHN B IIIEVP, Chief Financial Officer
62316
0.7205%
$4.3421+9.95%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Wells Fargo$1.17M5.12415,551-0.36%-$4,230.00<0.0001
Goldman Sachs$1.15M5.01406,6120%+$2.82<0.0001
The Vanguard Group$688,311.003.01244,0820%+$0<0.0001
Renaissance Technologies$615,000.002.69218,014-1.62%-$10,155.31<0.01
Acuitas Investments, LLC$396,743.001.73140,689+12.3%+$43,447.740.21
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.